Catalyst Calendar
Scope

Wed, Jun 3, 2026

1 updates
COCP
7:00 AM

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately....

cocrystalpharma.com

Tue, May 26, 2026

1 updates

Fri, May 15, 2026

1 updates
COCP
8:00 AM

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohorts Highlighted CDI-988’s mechanism of action and clinical advancement at ICAR 2026 Granted FDA Fast Track designation for CDI-988, enabling the potential for an...

Enrollment • Phase 1Enrollment completion Wed, Apr 1, 2026cocrystalpharma.com

Thu, Apr 30, 2026

1 updates
COCP
4:05 PM

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatment Fully enrolled first cohort is assessing the infectivity of the human challenge inoculum There are no approved treatments or vaccines for norovirus, the leading cause of acute gastroenteritis across...

Presentation / Abstract • Phase 1cocrystalpharma.com